Neoleukin stockholders approve reverse stock split and elect directors at 2023 annual meeting

5. Approval, by non-binding advisory vote, of the compensation paid by the Company to its named executive officers. Shares For Shares Against Shares Abstaining Broker Non-Votes 13,514,724 6,833,846 87,739 6,680,834

1. Election of three Class III Directors, M. Cantey Boyd, Rohan Palekar and Todd S. Simpson, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal. Nominees Shares For Shares Withheld Broker Non-Votes M. Cantey Boyd 19,947,525 488,784 6,680,834 Rohan Palekar 19,938,449 497,860 6,680,834 Todd S. Simpson 17,641,439 2,794,870 6,680,834

3. Approval of an amendment to the Certificate of Incorporation to permit the exculpation of officers from personal liability for certain breaches of the duty of care. Shares For Shares Against Shares Abstaining Broker Non-Votes 11,593,424 8,775,712 67,173 6,680,834

4. Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. Shares For Shares Against Shares Abstaining 26,983,470 60,815 72,858

2. Approval for the Company’s Board of Directors (the “Board”) to implement, at the Board's discretion, an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-5, with the exact ratio to be set within that range at the discretion of the Board prior to the one-year anniversary of the Annual Meeting without further approval or authorization of the stockholders, and a corresponding reduction in the number of authorized shares of common stock. Shares For Shares Against Shares Abstaining 26,231,211 827,666 58,266